Literature DB >> 23391636

Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.

Riina-Minna Väänänen1, Hans Lilja, Angel Cronin, Leni Kauko, Maria Rissanen, Otto Kauko, Henna Kekki, Siina Vidbäck, Martti Nurmi, Kalle Alanen, Kim Pettersson.   

Abstract

OBJECTIVES: The benefits of PSA (prostate specific antigen)-testing in prostate cancer remain controversial with a consequential need for validation of additional biomarkers. We used highly standardized reverse-transcription (RT)-PCR assays to compare transcript levels of 10 candidate cancer marker genes - BMP6, FGF-8b, KLK2, KLK3, KLK4, KLK15, MSMB, PCA3, PSCA and Trpm8 - in carefully ascertained non-cancerous versus cancerous prostate tissue from patients with clinically localized prostate cancer treated by radical prostatectomy. DESIGN AND METHODS: Total RNA was isolated from fresh frozen prostate tissue procured immediately after resection from two separate areas in each of 87 radical prostatectomy specimens. Subsequent histopathological assessment classified 86 samples as cancerous and 88 as histologically benign prostate tissue. Variation in total RNA recovery was accounted for by using external and internal standards and enabled us to measure transcript levels by RT-PCR in a highly quantitative manner.
RESULTS: Of the ten genes, there were significantly higher levels only of one of the less abundant transcripts, PCA3, in cancerous versus non-cancerous prostate tissue whereas PSCA mRNA levels were significantly lower in cancerous versus histologically benign tissue. Advanced pathologic stage was associated with significantly higher expression of KLK15 and PCA3 mRNAs. Median transcript levels of the most abundantly expressed genes (i.e. MSMB, KLK3, KLK4 and KLK2) in prostate tissue were up to 10(5)-fold higher than those of other gene targets.
CONCLUSIONS: PCA3 expression was associated with advanced pathological stage but the magnitude of overexpression of PCA3 in cancerous versus non-cancerous prostate tissue was modest compared to previously reported data.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391636      PMCID: PMC3628411          DOI: 10.1016/j.clinbiochem.2013.01.019

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  26 in total

1.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer.

Authors:  T Tsurusaki; T Koji; H Sakai; H Kanetake; P K Nakane; Y Saito
Journal:  Prostate       Date:  1998-05       Impact factor: 4.104

3.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Authors:  M F Darson; A Pacelli; P Roche; H G Rittenhouse; R L Wolfert; C Y Young; G G Klee; D J Tindall; D G Bostwick
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

4.  FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease.

Authors:  T J Dorkin; M C Robinson; C Marsh; A Bjartell; D E Neal; H Y Leung
Journal:  Oncogene       Date:  1999-04-29       Impact factor: 9.867

5.  Bone morphogenetic protein-6 expression in normal and malignant prostate.

Authors:  J Barnes; C T Anthony; N Wall; M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

6.  Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.

Authors:  Grégoire Robert; Sander Jannink; Frank Smit; Tilly Aalders; Daphne Hessels; Ruben Cremers; Peter F Mulders; Jack A Schalken
Journal:  Prostate       Date:  2012-06-05       Impact factor: 4.104

7.  Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.

Authors:  Zhijun Xi; Tove Irene Klokk; Kemal Korkmaz; Piotr Kurys; Cem Elbi; Bjørn Risberg; Håvard Danielsen; Massimo Loda; Fahri Saatcioglu
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

8.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

9.  FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer.

Authors:  Maija P Valta; Johanna Tuomela; Heikki Vuorikoski; Niina Loponen; Riina-Minna Väänänen; Kim Pettersson; H Kalervo Väänänen; Pirkko L Härkönen
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  4 in total

1.  Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Leni Kauko; Pauliina Helo; Henna Kekki; Angel M Cronin; Andrew J Vickers; Martti Nurmi; Kalle Alanen; Anders Bjartell; Kim Pettersson
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

2.  Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.

Authors:  Mesude Bicak; Katharina Lückerath; Teja Kalidindi; Michael E Phelps; Sven-Erik Strand; Michael J Morris; Caius G Radu; Robert Damoiseaux; Mari T Peltola; Norbert Peekhaus; Austin Ho; Darren Veach; Ann-Christin Malmborg Hager; Steven M Larson; Hans Lilja; Michael R McDevitt; Robert J Klein; David Ulmert
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-12       Impact factor: 11.205

3.  Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.

Authors:  Riina-Minna Väänänen; Natalia Tong Ochoa; Peter J Boström; Pekka Taimen; Kim Pettersson
Journal:  BMC Urol       Date:  2015-08-21       Impact factor: 2.264

4.  Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Authors:  Saeid Alinezhad; Riina-Minna Väänänen; Natalia Tong Ochoa; Emily A Vertosick; Anders Bjartell; Peter J Boström; Pekka Taimen; Kim Pettersson
Journal:  BMC Urol       Date:  2016-02-29       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.